Biostem Technologies (NASDAQ:BSEM) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Biostem Technologies (NASDAQ:BSEM) issued its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.10), Zacks reports. Biostem Technologies had a negative return on equity of 60.22% and a negative net margin of 76.02%.

Here are the key takeaways from Biostem Technologies’ conference call:

• BioStem raised the low end of its 2026 revenue guidance to $28 million–$29 million and expects sequential hospital-channel growth in Q4. Hospital revenue rose 2% sequentially to $6.8 million, although total Q3 revenue declined to $7.6 million from $7.9 million in Q2.
• The company is finalizing a cost-reduction plan expected to lower annualized cash operating expenses by $10 million–$12 million, with full benefits expected to begin in Q1 2027. It also expects to move Neox and Clarix manufacturing in-house in the first half of 2027, which management believes could lift gross margins by 10–15 percentage points over time.
• Commercial indicators included a 14% sequential increase in accounts buying at least two product lines and growth of more than 40% in accounts buying three or more. VENDAJE was added to agreements with two major GPOs, expanding access through existing hospital contracting channels.
• Q3 gross margin fell to 56% from 61% in Q2, and the adjusted EBITDA loss widened to $6.4 million from $4.6 million. Cash used in operating activities increased to $8.8 million, leaving $1 million in cash at quarter-end.
• BioStem is pursuing additional financing and working-capital options, and discussions to restructure an outstanding BioTissue clearance payment remain ongoing. The company has not drawn on its $40 million equity facility, but it may not be available until early April 2027 absent a waiver, and future use could dilute shareholders.

Biostem Technologies Trading Down 11.6%

Shares of BSEM stock traded down $0.17 during trading hours on Thursday, hitting $1.30. The company’s stock had a trading volume of 387,428 shares, compared to its average volume of 111,554. The stock has a market cap of $24.27 million, a PE ratio of -0.81 and a beta of 0.36. Biostem Technologies has a 12-month low of $1.00 and a 12-month high of $8.40. The company has a 50 day moving average of $2.68 and a 200 day moving average of $4.02.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Biostem Technologies to a “sell” rating in a report on Saturday, September 5th. Weiss Ratings began coverage on shares of Biostem Technologies in a research note on Wednesday, August 19th. They issued a “sell (d-)” rating for the company. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.00.

Biostem Technologies Company Profile

BioStem Technologies, Inc. is a biotechnology company focused on regenerative medicine and biologic tissue products. The company develops, manufactures and commercializes human tissue allografts intended to support wound care, tissue repair and other medical applications. Its product portfolio includes placental- and birth-tissue-derived products, such as amniotic membrane and umbilical cord allografts. These products are marketed for use by healthcare providers in areas including wound management, surgical procedures and related regenerative-care applications.